Jennifer Tousignant joined Viridian as Chief Legal Officer in 2024. Jennifer has broad legal experience and leadership in the biotechnology industry working across a breadth of technologies such as small molecules, biologics, cell and gene therapies, and in the therapeutic categories of rare disease, immune-mediated disease, neurodegenerative disease, and oncology. Prior to Viridian, Jennifer served as Senior Vice President of Legal for Sana Biotechnology where she was a leading a team responsible for legal support for strategic transactions, business development, intellectual property, litigation, quality, regulatory, research and development, investor relations, and general contracting as well as being involved in corporate governance and financings. She joined Sana from Xilio Therapeutics where she was the Head of Legal and responsible for all legal and compliance matters. Prior to Xilio, Jennifer was Chief IP Counsel at TESARO, where she built and led the intellectual property function, and was a key member of the global launch teams for several products. Before TESARO, she worked at Genzyme Corporation in roles of increasing responsibility, first in research and then in legal, and ultimately leading a legal team with worldwide intellectual property responsibility for products from early research to commercial.
Jennifer received her J.D. from Suffolk University School of Law, and her B.A. in Chemistry from the University of Virginia.
How do I contact Jennifer Tousignant?
Has Jennifer Tousignant been buying or selling shares of Viridian Therapeutics?
Jennifer Tousignant has not been actively trading shares of Viridian Therapeutics within the last three months. Most recently, Jennifer Tousignant sold 2,272 shares of the business's stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $31.16, for a transaction totalling $70,795.52. Learn More on Jennifer Tousignant's trading history.
Who are Viridian Therapeutics' active insiders?
Are insiders buying or selling shares of Viridian Therapeutics?
During the last twelve months, Viridian Therapeutics insiders bought shares 1 times. They purchased a total of 454,545 shares worth more than $9,999,990.00. During the last twelve months, insiders at the sold shares 1 times. They sold a total of 2,272 shares worth more than $70,795.52. The most recent insider tranaction occured on December, 31st when insider Jennifer Tousignant sold 2,272 shares worth more than $70,795.52. Insiders at Viridian Therapeutics own 1.6% of the company.
Learn More about insider trades at Viridian Therapeutics. Information on this page was last updated on 12/31/2025.
